Cue Biopharma Inc. has reached a preclinical milestone in its collaboration and license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, following the latter’s selection of a first compound for lead optimization. The milestone triggers a $7.5 million payment to Cue.
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.
